Key points are not available for this paper at this time.
Abstract Background The complex relationships between healthcare providers and pharmaceutical companies are under scrutiny due to the potential bias introduced by financial incentives. The Physician Payments Sunshine Act aims to ensure transparency. This study analyzes the trends of payments made to oncology physicians from 2016 to 2022, examining the amounts and reasons for these payments, and comparing them by subspecialties and regions. Methods A retrospective analysis of the Centers for Medicare and Medicaid Services Open Payments database was conducted, focusing on payments to oncologists. Payments were categorized by amount and purpose, with annual comparisons drawn between medical and hematologic oncologists. U. S. regional distribution was also analyzed. Data management was performed using Microsoft Excel, and statistical analyses were carried out with IBM SPSS Version 25, utilizing descriptive statistics and visualization tools. Results Oncologists received 2, 439, 799 payments totaling 620, 795, 774 over the seven years. The majority (70. 3%) were small (11 to 50), indicating a trend of modest but frequent financial interactions. The most funded categories were compensation for non-consulting services (39. 33%) and consulting fees (35. 17%). While "Food and Beverage" payments were most frequent, accounting for over 80% of interactions, they comprised only 7. 48% of the total payment amount. A significant payment peak occurred in 2020, especially among medical oncologists. Geographically, Northeast U. S. oncologists received fewer yet higher-valued payments than their Southern counterparts. Payment amounts varied significantly across specialties, with cardiologists receiving the highest total payments and hematologists the highest mean payments. Conclusions The analysis reveals that while the majority of payments to oncologists are for relatively minor amounts, the distribution is uneven across regions and specialties. The surge in payments in 2020 may reflect the introduction of expensive oncology drugs, underscoring the need for ongoing scrutiny of these financial relationships to maintain ethical clinical practices.
Zhao et al. (Thu,) studied this question.